Treatment Guidance•Evidence reviewed September 2026•14 min read

Semaglutide vs Tirzepatide for Weight Loss: Head-to-Head Comparison with 2026 Trial Data

A direct comparison of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) for weight loss, covering SURMOUNT-5 results, the 2026 meta-analysis of 41,381 patients, side-effect profiles, cardiovascular evidence, and a practical decision framework for choosing between them.

Written by OffRamp GLP-1 Editorial TeamReviewed by OffRamp GLP-1 Research Team

The two most prescribed GLP-1 drugs are not interchangeable, and the right choice depends on your priority

Searches like "semaglutide vs tirzepatide" and "Ozempic vs Mounjaro" consistently rank among the most common GLP-1 questions. The short answer: tirzepatide produces greater average weight loss, but the trade-offs, cost, cardiovascular evidence, tolerability, and access, are not captured in the averages.

"Which one works better?" "Should I start with Ozempic or go straight to Zepbound?" "My friend lost twice as much on Mounjaro, should I switch?" These questions show up in GLP-1 communities daily, often from people trying to choose between semaglutide and tirzepatide with only marketing summaries and anecdotal comparisons to guide them.

The evidence base for answering this question is stronger than it was even a year ago. A 2026 systematic review and meta-analysis in Clinical Obesity (Paccola et al., 10 studies, 41,381 participants) provides the most comprehensive head-to-head synthesis to date. The SURMOUNT-5 trial published 72-week results comparing tirzepatide 15mg against semaglutide 2.4mg. A JAMA Internal Medicine real-world cohort study matched 18,386 patients. And a new higher-dose semaglutide formulation, Wegovy HD 7.2mg, has started to close the efficacy gap.

This guide synthesizes the head-to-head evidence into a framework that goes beyond averages: how the drugs differ in mechanism, weight-loss outcomes, side-effect profiles, cardiovascular protection, cost, and which patient characteristics may tilt the choice one way or the other.

Key highlights

  • •Tirzepatide produces approximately 4 to 7 percentage points greater average weight loss than semaglutide across the head-to-head evidence, 20.2% vs 13.7% in SURMOUNT-5 at 72 weeks.
  • •Gastrointestinal side effects (nausea, diarrhea, vomiting) occur at similar rates between the two drugs, but tirzepatide shows a higher risk of serious adverse events in the pooled meta-analysis (RR 1.83).
  • •Semaglutide has the most mature cardiovascular outcome data, SELECT showed a 20% MACE reduction. Tirzepatide has demonstrated non-inferiority but not superiority for cardiovascular events.
  • •Wegovy HD (semaglutide 7.2mg), approved in 2026, produced ~21% weight loss in the STEP UP trial, narrowing the gap between semaglutide and tirzepatide for patients who tolerate high doses.

How semaglutide and tirzepatide work differently

Semaglutide (Ozempic, Wegovy, Wegovy HD, Rybelsus) is a GLP-1 receptor agonist. It mimics the glucagon-like peptide-1 hormone, which stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system GLP-1 receptor activation. It targets a single receptor pathway.

Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist. In addition to activating GLP-1 receptors, it also activates glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual mechanism is thought to produce complementary metabolic effects: GIP agonism may enhance insulin sensitivity, promote energy expenditure, and amplify the weight-loss signal beyond what GLP-1 activation alone achieves. A 2026 Frontiers in Medicine narrative review describes the dual-incretin approach as offering "enhanced metabolic benefits compared with selective GLP-1 receptor agonists."

In practical terms: both drugs reduce appetite and slow digestion. Tirzepatide adds a second signaling pathway that appears to drive greater average weight loss, but individual response varies, and the mechanism difference does not guarantee superiority for every patient.

Weight loss: the head-to-head numbers

The SURMOUNT-5 trial is the most direct head-to-head comparison currently available. At 72 weeks, tirzepatide 15mg produced an estimated mean body weight reduction of 20.2% compared with 13.7% for semaglutide 2.4mg among adults with overweight or obesity without diabetes. The difference in responder rates was similarly pronounced: 50% of tirzepatide participants achieved at least 20% weight loss versus 27% on semaglutide; 33% versus 16% achieved at least 25%.

A 2026 systematic review and meta-analysis in Clinical Obesity (Paccola et al.) pooled 10 head-to-head studies including 41,381 participants. The pooled analysis showed tirzepatide was associated with a mean difference of −4.28 percentage points (95% CI −5.28 to −3.28) in weight reduction compared with semaglutide, and −4.43 kg greater absolute weight loss. Tirzepatide was significantly more likely to achieve ≥10% weight loss (RR 1.43), ≥15% (RR 1.85), and ≥20% (RR 2.03), with no significant difference at the ≥5% threshold.

A real-world cohort study published in JAMA Internal Medicine (2024) matched 18,386 patients and found tirzepatide produced larger on-treatment weight reductions at every time point: −5.9% vs −3.6% at 3 months, −10.1% vs −5.8% at 6 months, and −15.3% vs −8.3% at 12 months. The hazard ratios favored tirzepatide at every weight-loss threshold: 1.76 for ≥5%, 2.54 for ≥10%, and 3.24 for ≥15% weight loss. Notably, discontinuation rates were high in both groups, 55.9% for tirzepatide and 52.5% for semaglutide, reflecting the real-world challenge of tolerability and adherence.

Both drugs show significant heterogeneity in individual response. Substantial heterogeneity was observed in the meta-analysis (I² = 90% for percentage weight change), meaning averages describe the population but not the individual. Some people lose more weight on semaglutide than tirzepatide, and some respond poorly to both.

Wegovy HD: the new variable in the comparison

Wegovy HD (semaglutide 7.2mg weekly injection) was approved in 2026 for adults with obesity who have tolerated the 2.4mg dose for at least 4 weeks and need additional weight loss. The STEP UP trial showed that Wegovy HD produced approximately 21% average weight loss, approaching the 22.5% seen with tirzepatide 15mg in SURMOUNT-1.

This changes the comparison meaningfully. When tirzepatide (15mg) is compared against the standard 2.4mg semaglutide dose, the gap is approximately 6 to 7 percentage points. When tirzepatide (15mg) is compared against Wegovy HD (7.2mg), the gap narrows to approximately 1 to 2 percentage points, a difference that may not be clinically meaningful for many patients.

The trade-off: Wegovy HD carries higher rates of gastrointestinal side effects than the 2.4mg dose. In the STEP UP trial, nausea rates increased with dose escalation, and tolerability remains the limiting factor for high-dose semaglutide. Wegovy HD is not a first-titration option, patients must demonstrate tolerance to 2.4mg before stepping up. No direct head-to-head trial currently exists comparing Wegovy HD against tirzepatide 15mg.

Side effect comparison: similar GI burden, different serious-event profile

Gastrointestinal side effects are the most common tolerability challenge for both drugs. In SURMOUNT-5, GI adverse event rates were similar between tirzepatide and semaglutide (17–22% across both groups). The meta-analysis confirmed that overall GI adverse events and treatment discontinuation due to adverse events did not differ significantly between the two drugs (RR 1.28; p = 0.54). Nausea rates in the STEP 1 trial were approximately 44% for semaglutide and 27–30% for tirzepatide, though direct comparisons within head-to-head trials show more comparable rates.

The important difference: serious adverse events (SAEs) were significantly higher with tirzepatide in the pooled meta-analysis (RR 1.83; p = 0.007). The Frontiers in Medicine narrative review describes this as a "higher risk of serious adverse events in direct comparative analyses." The clinical significance of this finding depends on the individual: SAEs in GLP-1 trials are uncommon overall, and the absolute risk increase is small, but it is a data point worth considering for patients with risk factors.

Tirzepatide showed slightly higher rates of hypoglycemia (0.2–1.7% vs 0.4% for semaglutide) in SURPASS-2, though this is primarily relevant for patients with diabetes, particularly those also taking insulin or sulfonylureas. For patients without diabetes on a GLP-1 for weight loss alone, hypoglycemia risk is very low for both drugs.

Cardiovascular evidence: semaglutide has the data, tirzepatide has the potential

This is the area where the comparison shifts most. Semaglutide has multiple dedicated cardiovascular outcome trials (CVOTs). SELECT, the largest GLP-1 CVOT to date, showed a 20% reduction in three-point MACE (cardiovascular death, myocardial infarction, stroke) in adults with overweight or obesity and established cardiovascular disease but without diabetes. SUSTAIN-6 and PIONEER-6 demonstrated significant cardiovascular benefit in type 2 diabetes. These trials give semaglutide the most mature cardiovascular evidence base of any GLP-1 drug currently approved for weight management.

Tirzepatide has not yet demonstrated superior cardiovascular outcomes in a dedicated trial. The SURPASS-CVOT trial established non-inferiority to dulaglutide (a GLP-1 agonist with its own CVOT data) for three-point MACE, with a directional hazard ratio of approximately 0.90–0.95 that favored tirzepatide without reaching superiority. The Frontiers in Medicine review notes that "semaglutide currently has the strongest evidence for cardiovascular benefit" while tirzepatide shows "non-inferiority alongside improvements in cardiometabolic risk factors."

In practical terms: for a patient with established cardiovascular disease, heart failure, or high cardiovascular risk, the decision should account for semaglutide's more robust CVOT evidence. For a patient whose primary goal is maximum weight loss without established cardiovascular disease, the SURMOUNT-5 efficacy data and SURPASS-CVOT safety signal support tirzepatide as a reasonable option. The SURMOUNT-CVOT trial, which is expected to provide direct cardiovascular outcome data for tirzepatide, has not yet reported.

Cost, insurance, and access differences

Access and cost are often the deciding factors that override clinical preference. Both drugs are brand-name and expensive without coverage. As of mid-2026, Wegovy and Ozempic (semaglutide) have broader insurance formulary coverage in many US plans due to longer market presence and established cardiovascular indications. Wegovy recently received Medicare Part D coverage under the GLP-1 Bridge Program (July–December 2026) for patients with obesity, expanding access significantly.

Tirzepatide (Zepbound for weight loss) has narrower but growing coverage. Zepbound was added to some major formularies in 2025–2026 but prior authorization requirements remain stricter than for Wegovy. Mounjaro (tirzepatide for diabetes) has broader coverage than Zepbound, but weight-loss prescribing requires the Zepbound label.

Compounded versions add another dimension. The June 2026 FDA compounding crackdown restricted 503A compounding of tirzepatide and semaglutide, though the landscape continues to evolve. Patients relying on compounded GLP-1s for affordability should discuss continuity planning with their prescriber, as access to branded versions through insurance or manufacturer savings programs may require advance planning.

Decision framework: which one for whom

The evidence supports individualizing the choice rather than declaring one drug universally superior. The following framework synthesizes the head-to-head data into clinical scenarios:

Choose tirzepatide when: the primary goal is maximum weight loss and cardiovascular disease is not a primary concern; the patient has a high weight-loss target (≥20% of body weight); or the patient has tried semaglutide and plateaued on the maximum tolerated dose. Tirzepatide is also the rational choice for patients who want the highest probability of aggressive weight loss and can tolerate the GI side-effect profile.

Choose semaglutide when: the patient has established cardiovascular disease, high cardiovascular risk, or multiple cardiovascular risk factors; cost and insurance access are primary constraints; the patient prefers a longer track record with more mature safety data; or the patient has a moderate weight-loss target (10–15% of body weight) that either drug can likely achieve. Wegovy HD (7.2mg) should be considered for patients who tolerate 2.4mg well and want additional weight loss without switching drug classes.

The neutral option: start with whichever drug is accessible through insurance and best tolerated during the first 8 weeks, then reassess. Many patients achieve clinically meaningful weight loss on both drugs, and the "better" drug is the one a patient actually tolerates and stays on. The discontinuation rates in both arms of the real-world study (~53–56%) underscore that persistence matters more than the starting choice.

What the 2026 meta-analysis adds that individual trials miss

The Paccola et al. meta-analysis (Clinical Obesity, 2026) is the most comprehensive synthesis of head-to-head data between tirzepatide and semaglutide published to date. By pooling 10 studies with 41,381 participants, it addresses two questions individual trials cannot answer: consistency of the treatment effect across populations, and safety signals that may not appear in a single trial.

The consistency finding is notable: all 10 studies favored tirzepatide for weight reduction, even though heterogeneity in magnitude was high (I² = 90%). This means the direction of effect is reliable even if the exact size varies. The safety finding, higher SAEs with tirzepatide (RR 1.83), emerged only in the pooled analysis and would not have been detectable in any single trial. This is the kind of signal that warrants discussion between patient and prescriber, not automatic avoidance.

The meta-analysis was limited by heterogeneity in study design, follow-up duration (≥24 weeks minimum), and population characteristics. Subgroup analyses by study design and type 2 diabetes status yielded consistent findings, supporting the robustness of the direction of effect while leaving uncertainty around the precise magnitude.

Practical next steps

If you are choosing between semaglutide and tirzepatide for the first time: discuss the decision framework above with your prescriber. Bring your medical history, especially any history of cardiovascular disease, pancreatitis, or significant GI conditions, and your weight-loss goal in percentage terms, not pounds alone. Ask your insurance provider which drug is covered at the lowest out-of-pocket cost.

If you are considering switching from one to the other: review the OffRamp GLP-1 switching guide (/guide/glp1-switching-medications) for the protocol. The standard approach is to restart the new drug at its lowest dose regardless of your previous dose.

Whichever drug you and your prescriber choose, the non-negotiable supports are the same: 100g+ protein daily, resistance training, hydration (2.5–3L daily), and symptom tracking. No drug, semaglutide or tirzepatide, replaces these foundations. The OffRamp GLP-1 tracker is free and designed for this exact purpose: tracking dose timing, symptoms, weight, protein intake, and hydration in one place.

Frequently asked questions

Which is better for weight loss: semaglutide or tirzepatide?

Across the head-to-head evidence, tirzepatide produces greater average weight loss. In SURMOUNT-5, tirzepatide achieved 20.2% weight loss vs 13.7% for semaglutide at 72 weeks. A 2026 meta-analysis of 10 studies with 41,381 participants showed tirzepatide produced approximately 4.3 percentage points greater weight loss on average. However, Wegovy HD 7.2mg (approved 2026) narrows this gap to about 1–2 percentage points for patients who tolerate high-dose semaglutide.

Is tirzepatide safer than semaglutide?

Gastrointestinal side effects occur at similar rates between the two drugs. However, the 2026 meta-analysis found a higher risk of serious adverse events with tirzepatide (RR 1.83), though the absolute risk is small. Semaglutide has more robust cardiovascular outcome data (SELECT trial showed 20% MACE reduction), while tirzepatide has demonstrated cardiovascular safety but not superiority. The choice should account for individual cardiovascular risk and tolerability.

Can I switch from semaglutide to tirzepatide?

Yes, under clinician guidance. The standard protocol is to start tirzepatide at 2.5mg weekly regardless of your previous semaglutide dose, then titrate up every 4 weeks. Your prescriber will determine whether a 1-to-2-week washout or a same-day switch is appropriate based on your side-effect history. See the OffRamp GLP-1 switching guide for the full protocol.

Does Wegovy HD change the semaglutide vs tirzepatide comparison?

Yes. Wegovy HD (semaglutide 7.2mg) produced approximately 21% average weight loss in STEP UP, approaching the 22.5% seen with tirzepatide 15mg in SURMOUNT-1. This narrows the efficacy gap from ~6 percentage points to ~1–2 percentage points. The trade-off is higher GI side-effect rates at the 7.2mg dose. No direct head-to-head trial of Wegovy HD vs tirzepatide 15mg currently exists.

Does tirzepatide cause more side effects than semaglutide?

The GI side-effect rates are broadly similar between the two drugs in head-to-head trials (17–22% across both groups in SURMOUNT-5). The meta-analysis found no significant difference in treatment discontinuation due to adverse events. However, serious adverse events were higher with tirzepatide in the pooled analysis (RR 1.83). Individual tolerability varies enough that trying one and switching if intolerable is a reasonable approach.

How do I choose between semaglutide and tirzepatide?

Choose tirzepatide if your primary goal is maximum weight loss and you do not have established cardiovascular disease. Choose semaglutide if you have cardiovascular disease, cost and insurance coverage are primary constraints, or you prefer a longer safety track record. For many patients, the best choice is whichever drug is covered by insurance and tolerated during the first 8 weeks, persistence matters more than the starting drug.

Does one drug have better cardiovascular protection?

Semaglutide has the more robust cardiovascular evidence base. The SELECT trial showed a 20% reduction in MACE in patients without diabetes, and SUSTAIN-6/PIONEER-6 demonstrated CV benefit in type 2 diabetes. Tirzepatide has established non-inferiority to dulaglutide (SURPASS-CVOT) but has not demonstrated superiority for CV outcomes. For patients with established cardiovascular disease, semaglutide is the evidence-supported choice.

Can I take semaglutide and tirzepatide together?

No. Taking both drugs simultaneously is not recommended and has not been studied. Both affect GLP-1 receptors (tirzepatide also activates GIP receptors), and concurrent use would amplify side effects, particularly GI symptoms, without evidence of additional benefit. Always use one GLP-1 drug at a time under clinician supervision.

Sources

This guide synthesizes data from the SURMOUNT-5 and STEP trial programs, the Paccola et al. 2026 systematic review and meta-analysis (Clinical Obesity), the JAMA Internal Medicine comparative effectiveness cohort study (Rodriguez et al., 2024), the Frontiers in Medicine narrative review, SELECT and SURPASS-CVOT cardiovascular outcome trials, and current U.S. prescribing information for Wegovy, Wegovy HD, and Zepbound. Educational only, not a substitute for clinical advice.

The two most prescribed GLP-1 drugs are not interchangeable, and the right choice depends on your priority

Searches like "semaglutide vs tirzepatide" and "Ozempic vs Mounjaro" consistently rank among the most common GLP-1 questions. The short answer: tirzepatide produces greater average weight loss, but the trade-offs, cost, cardiovascular evidence, tolerability, and access, are not captured in the averages.

Track your GLP-1 journey free, doses, weight, symptoms, and protein →
This page is for general education only. It is not medical advice and should not replace care from your licensed healthcare provider.